EUVIMEDEUVIMED entdecken
Leserbrief

Clarifying the romosozumab “Super-Responder” phenotype: response to methodological concerns

Alberto Ghielmetti, Giorgia Grassi, Cristina Eller-Vainicher

Osteoporosis International · 2026-10 · 37 (10) · 2779-2780

DOI: 10.1007/s00198-026-08130-2 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Osteoporosis International, online erschienen am 06.07.2026. Verfasst von Alberto Ghielmetti und 2 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Endocrinology and Metabolism, University Hospital Santa Maria Della Misericordia, 33100, Udine, Italy. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Unit of Endocrinology and Metabolism, University Hospital Santa Maria Della Misericordia, 33100, Udine, Italy.
  • Endocrine Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, 20122, Milan, Italy.
  • Endocrine Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, 20122, Milan, Italy. cristina.eller@policlinico.mi.it.

Zitieren

APA

Ghielmetti, A., Grassi, G., & Eller-Vainicher, C. (2026). Clarifying the romosozumab “Super-Responder” phenotype: response to methodological concerns. Osteoporosis International, 37(10), 2779-2780. https://doi.org/10.1007/s00198-026-08130-2

Vancouver

Ghielmetti A, Grassi G, Eller-Vainicher C. Clarifying the romosozumab “Super-Responder” phenotype: response to methodological concerns. Osteoporosis International. 2026;37(10):2779-2780. doi:10.1007/s00198-026-08130-2

BibTeX
@article{Ghielmetti2026,
  author = {Ghielmetti, Alberto and Grassi, Giorgia and Eller-Vainicher, Cristina},
  title = {Clarifying the romosozumab “Super-Responder” phenotype: response to methodological concerns},
  journal = {Osteoporosis International},
  year = {2026},
  volume = {37},
  number = {10},
  pages = {2779--2780},
  doi = {10.1007/s00198-026-08130-2}
}
Kostenlos starten →